| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 99.88K | 123.82K | 0 | 8.56K | 156.42K | 6.33K |
| Revenue Growth % | - | 0.24% | -1% | - | 17.27% | -0.96% |
| Cost of Goods Sold | 54.13K | 133.25K | 0 | 9.93K | 105.83K | 59.4K |
| COGS % of Revenue | 0.54% | 1.08% | - | 1.16% | 0.68% | 9.38% |
| Gross Profit | 45.75K | -9.43K | 0 | -1.36K | 50.59K | -53.07K |
| Gross Margin % | 0.46% | -0.08% | - | -0.16% | 0.32% | -8.38% |
| Gross Profit Growth % | - | -1.21% | 1% | - | 38.06% | -2.05% |
| Operating Expenses | 696.99K | 635.1K | 1.73M | 5.73M | 6.55M | 6.11M |
| OpEx % of Revenue | 6.98% | 5.13% | - | 669.48% | 41.86% | 965.07% |
| Selling, General & Admin | 609.99K | 514.88K | 1.3M | 5.33M | 4.59M | 4.33M |
| SG&A % of Revenue | 6.11% | 4.16% | - | 623.09% | 29.37% | 683.94% |
| Research & Development | 87K | 120.22K | 433.74K | 397.11K | 1.56M | 1.78M |
| R&D % of Revenue | 0.87% | 0.97% | - | 46.39% | 9.99% | 281.12% |
| Other Operating Expenses | 2.47K | 266 | 0 | 0 | 390.36K | 0 |
| Operating Income | -651.24K | -644.54K | -1.73M | -5.73M | -6.5M | -6.16M |
| Operating Margin % | -6.52% | -5.21% | - | -669.64% | -41.53% | -973.45% |
| Operating Income Growth % | - | 0.01% | -1.69% | -2.31% | -0.13% | 0.05% |
| EBITDA | 0 | -2 | -1 | -5.44M | -6.39M | -5.82M |
| EBITDA Margin % | - | -0% | - | -635.71% | -40.87% | -919.21% |
| EBITDA Growth % | - | - | 0.5% | -999999% | -0.17% | 0.09% |
| D&A (Non-Cash Add-back) | 651.24K | 644.54K | 1.73M | 0 | 103.1K | 343.39K |
| EBIT | -648.77K | -644.27K | -1.73M | -5.44M | -6.71M | -6.15M |
| Net Interest Income | -90.69K | -28.64K | 0 | -15.47K | -26.88K | -58.18K |
| Interest Income | 0 | 0 | 15.44K | 0 | 0 | 0 |
| Interest Expense | 90.69K | 28.64K | 15.44K | 15.47K | 26.88K | 58.18K |
| Other Income/Expense | -88.22K | -28.38K | -16.19K | 275K | -242.65K | -41K |
| Pretax Income | -739.46K | -672.91K | -1.75M | -5.46M | -6.74M | -6.2M |
| Pretax Margin % | -7.4% | -5.43% | - | -637.51% | -43.08% | -979.92% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -136.66K |
| Effective Tax Rate % | 1.08% | 0.97% | 0.98% | 1% | 1% | 0.98% |
| Net Income | -801.13K | -650.98K | -1.71M | -5.46M | -6.73M | -6.06M |
| Net Margin % | -8.02% | -5.26% | - | -637.48% | -43.05% | -957.39% |
| Net Income Growth % | - | 0.19% | -1.62% | -2.19% | -0.23% | 0.1% |
| Net Income (Continuing) | -739.46K | -672.91K | -1.75M | -5.46M | -6.74M | -6.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -159.03K | -181.13K | -222.13K | -222.4K | -227.98K | -233.97K |
| EPS (Diluted) | -0.70 | -0.57 | -1.50 | -5.13 | -3.36 | -1.95 |
| EPS Growth % | - | 0.19% | -1.63% | -2.42% | 0.35% | 0.42% |
| EPS (Basic) | -0.70 | -0.57 | -1.50 | -5.13 | -3.36 | -1.96 |
| Diluted Shares Outstanding | 1.14M | 1.14M | 1.14M | 1.06M | 2.01M | 3.1M |
| Basic Shares Outstanding | 1.14M | 1.14M | 1.14M | 1.06M | 2.01M | 3.1M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 22.61K | 39.62K | 48.71K | 9.63M | 4.38M | 4.89M |
| Cash & Short-Term Investments | 22.61K | 17.62K | 21.76K | 9.35M | 3.59M | 4.23M |
| Cash Only | 22.61K | 17.62K | 21.76K | 9.35M | 3.59M | 4.23M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 928 | 0 | 0 | 217.84K | 30.65K |
| Days Sales Outstanding | - | 2.74 | - | - | 508.33 | 1.77K |
| Inventory | 0 | 21.07K | 20.95K | 24.09K | 60.38K | 94.67K |
| Days Inventory Outstanding | - | 57.72 | - | 886.02 | 208.26 | 581.78 |
| Other Current Assets | 0 | 0 | 0 | 0 | 77.32K | 0 |
| Total Non-Current Assets | 0 | 54.5K | 0 | 178.4K | 1.1M | 1.53M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 1.1M | 1.53M |
| Fixed Asset Turnover | - | - | - | - | 0.14x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 178.4K | 49.77K | 39.65K |
| Long-Term Investments | 0 | 54.5K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | -178.4K | -49.77K | -39.65K |
| Total Assets | 22.61K | 94.12K | 48.71K | 9.81M | 5.48M | 6.43M |
| Asset Turnover | 4.42x | 1.32x | - | 0.00x | 0.03x | 0.00x |
| Asset Growth % | - | 3.16% | -0.48% | 200.46% | -0.44% | 0.17% |
| Total Current Liabilities | 1.24M | 871.43K | 1.25M | 908.4K | 168.85K | 673.21K |
| Accounts Payable | 212.84K | 217.15K | 846.47K | 159.91K | 45.63K | 56.09K |
| Days Payables Outstanding | 1.44K | 594.79 | - | 5.88K | 157.38 | 344.69 |
| Short-Term Debt | 759.37K | 0 | 0 | 146.25K | 0 | 32.47K |
| Deferred Revenue (Current) | -759.37K | 0 | 0 | 38.25K | 0 | 0 |
| Other Current Liabilities | 11.47K | 192K | 3.76K | 140.29K | 63.12K | 60.48K |
| Current Ratio | 0.02x | 0.05x | 0.04x | 10.61x | 25.94x | 7.27x |
| Quick Ratio | 0.02x | 0.02x | 0.02x | 10.58x | 25.58x | 7.13x |
| Cash Conversion Cycle | - | -534.33 | - | - | 559.21 | 2K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 176.34K | 291.54K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 176.34K | 291.54K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.24M | 871.43K | 1.25M | 908.4K | 345.19K | 964.75K |
| Total Debt | 759.37K | 179.48K | 3.76K | 146.25K | 224.3K | 377K |
| Net Debt | 736.76K | 161.86K | -18K | -9.21M | -3.36M | -3.85M |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -7.18x | -22.50x | -112.30x | -370.62x | -241.70x | -105.93x |
| Total Equity | -1.22M | -777.32K | -1.2M | 8.9M | 5.14M | 5.46M |
| Equity Growth % | - | 0.36% | -0.54% | 8.44% | -0.42% | 0.06% |
| Book Value per Share | -1.07 | -0.68 | -1.05 | 8.38 | 2.56 | 1.76 |
| Total Shareholders' Equity | -1.06M | -596.18K | -974.58K | 9.13M | 5.37M | 5.7M |
| Common Stock | 104 | 265 | 999 | 1.56K | 2.57K | 4.34K |
| Retained Earnings | -3.98M | -4.63M | -6.34M | -11.79M | -18.53M | -24.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.92M | 4.03M | 5.36M | 20.92M | 23.89M | 30.28M |
| Minority Interest | -159.03K | -181.13K | -222.13K | -222.4K | -227.98K | -233.97K |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -744.61K | -590.19K | -809.07K | -4.18M | -6.25M | -4.56M |
| Operating CF Margin % | -7.46% | -4.77% | - | -488.23% | -39.94% | -720.83% |
| Operating CF Growth % | - | 0.21% | -0.37% | -4.17% | -0.49% | 0.27% |
| Net Income | -739.46K | -650.98K | -1.71M | -5.46M | -6.74M | -6.07M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 103.1K | 343.39K |
| Stock-Based Compensation | 0 | 0 | 290.36K | 1.73M | 1.01M | 365.31K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 91.67K | 1.19K | -32.07K | -260.6K | 497.06K | 169.34K |
| Working Capital Changes | -96.82K | 59.61K | 644.39K | -216.28K | -1.12M | 625.62K |
| Change in Receivables | 0 | -928 | 928 | 0 | -217.84K | 219.66K |
| Change in Inventory | 0 | -21.07K | 121 | 20.95K | -60.38K | -34.29K |
| Change in Payables | -96.82K | 81.61K | 641.16K | 33.94K | -572.25K | 466.85K |
| Cash from Investing | 0 | 0 | 0 | -178.4K | -1.16M | -603.89K |
| Capital Expenditures | 0 | 0 | 0 | -178.4K | -952.5K | -603.89K |
| CapEx % of Revenue | - | - | - | 20.84% | 6.09% | 95.39% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -178.4K | -211.95K | 0 |
| Cash from Financing | 704.64K | 585.2K | 813.21K | 13.69M | 1.65M | 5.81M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 704.64K | 585.2K | 193.59K | -111.64K | 1.85M | 786.74K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -744.61K | -590.19K | -809.07K | -4.36M | -7.41M | -5.17M |
| FCF Margin % | -7.46% | -4.77% | - | -509.07% | -47.38% | -816.22% |
| FCF Growth % | - | 0.21% | -0.37% | -4.39% | -0.7% | 0.3% |
| FCF per Share | -0.65 | -0.52 | -0.71 | -4.10 | -3.69 | -1.67 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.91x | 0.47x | 0.77x | 0.93x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 78.95K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -141.62% | -95.9% | -114.35% |
| Return on Invested Capital (ROIC) | - | - | - | - | -662.2% | -273.17% |
| Gross Margin | 45.81% | -7.62% | - | -15.94% | 32.34% | -838.21% |
| Net Margin | -802.13% | -525.75% | - | -63748.32% | -4304.81% | -95739.17% |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.07x |
| Interest Coverage | -7.18x | -22.50x | -112.30x | -370.62x | -241.70x | -105.93x |
| FCF Conversion | 0.93x | 0.91x | 0.47x | 0.77x | 0.93x | 0.75x |
| Revenue Growth | - | 23.97% | -100% | - | 1727.11% | -95.95% |
Virax Biolabs Group Limited (VRAX) reported $0.2M in revenue for fiscal year 2025. This represents a 63% increase from $0.1M in 2020.
Virax Biolabs Group Limited (VRAX) saw revenue decline by 96.0% over the past year.
Virax Biolabs Group Limited (VRAX) reported a net loss of $12.8M for fiscal year 2025.
Virax Biolabs Group Limited (VRAX) has a return on equity (ROE) of -114.4%. Negative ROE indicates the company is unprofitable.
Virax Biolabs Group Limited (VRAX) had negative free cash flow of $12.6M in fiscal year 2025, likely due to heavy capital investments.